
Product Data Sheet

Product Name: Bcl-xL antagonist 2

Cat. No.: GC63325

Chemical Properties

Cas. No. 1235032-75-3

Formula $C_{21}H_{16}N_4O_3S_2$

M.Wt 436.51

Solubility DMSO : 62.5 mg/mL (143.18 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC₅₀ and K_i of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL)[1][2].

Assessment of Pharmacokinetics (PK) profile of Bcl-xL antagonist 2 (compound 14) in rat[1]. iv (1 mg/kg) po (5 mg/kg) CLp (mL/min/kg) Vss (L/kg) t_{1/2} (h) F % 0.47 0.16 6.0 16

[1]. Koehler MF, et al. Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL. ACS Med Chem Lett. 2014;5(6):662-667.

[2]. Wang L, et al. Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor. ACS Med Chem Lett. 2020;11(10):1829-1836.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA